Placebo News and Research

RSS

Memantine boosts memory function in people with Down syndrome

Researchers at the University of Colorado School of Medicine have found a drug that boosts memory function in those with Down syndrome, a major milestone in the treatment of this genetic disorder that could significantly improve quality of life.

18 Jul 2012

Anthera announces final set of clinical data from blisibimod Phase 2b study on SLE

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced the final set of clinical data from the Phase 2b PEARL-SC study in patients with systemic lupus erythematosus.

17 Jul 2012

Healthier levels of vitamin C can reduce inflammatory conditions

The recommended dietary allowance, or RDA, of vitamin C is less than half what it should be, scientists argue in a recent report, because medical experts insist on evaluating this natural, but critical nutrient in the same way they do pharmaceutical drugs and reach faulty conclusions as a result.

17 Jul 2012

U.S. FDA approves Gilead’s Truvada to minimize risk of sexually-acquired HIV infection

Today, the U.S. Food and Drug Administration approved Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners. Truto reduce the risk of sexually-acquired HIV infection in adults at high risk.

17 Jul 2012

AstraZeneca plans to conduct ticagrelor plus clopidogrel clinical trial for PAD

AstraZeneca today announced plans to conduct the EUCLID study, a global clinical trial involving 11,500 patients with peripheral artery disease (PAD), a condition affecting approximately 27 million people in Europe and North America.

17 Jul 2012

D-ribose effective in improving QOL in energy-depleted patients with FMS/CFS

A new multicenter study published in The Open Pain Journal showed that daily consumption of the pentose carbohydrate D-ribose resulted in an average energy boost of 61 percent among patients diagnosed with Chronic Fatigue Syndrome (CFS) and fibromyalgia (FMS).

17 Jul 2012

Gilead receives FDA approval for Truvada to reduce risk of sexually acquired HIV-1 infection

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada (emtricitabine and tenofovir disoproxil fumarate), in combination with safer sex practices, to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.

17 Jul 2012

Positive results from Alnylam’s ALN-TTR02 Phase I trial on TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the achievement of positive clinical results from its Phase I trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis.

16 Jul 2012

Merck to present results from clinical studies on BACE inhibitors at AAIC 2012

Merck, known as MSD outside the United States and Canada, announced today presentations at the upcoming Alzheimer's Association International Conference (AAIC) being held in Vancouver, British Columbia, Canada on July 14-19, 2012.

16 Jul 2012

UCB’s Neupro now available in U.S. pharmacies

UCB announced today that Neupro (Rotigotine Transdermal System) is now available in U.S. pharmacies. Neupro was approved by the U.S Food and Drug Administration in April to treat the signs and symptoms of early and advanced stage idiopathic Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome.

16 Jul 2012

Vitamin D deficiency may impair lung function in asthmatic children treated with budesonide

Vitamin D deficiency is associated with poorer lung function in asthmatic children treated with inhaled corticosteroids, according to a new study from researchers in Boston.

14 Jul 2012

Viewpoints: Wis. Gov. calls Obamacare 'bad policy;' 'Do the math' before deciding on Medicaid expansion

Since the Supreme Court upheld President Obama's health-care mandate, there has been exhaustive discussion about the philosophical basis of this federal law. As Election Day approaches, debate will surely grow about the proper role of our federal government. But while much attention has focused on Congress's intention to repeal or replace the Affordable Care Act, too few are studying the law's practical impact.

14 Jul 2012

Negative suggestion can induce symptoms of illness

Negative suggestion can induce symptoms of illness. Nocebo effects are the adverse events that occur during sham treatment and/or as a result of negative expectations. While the positive counterpart—the placebo effect—has been intensively studied in recent years, the scientific literature contains few studies on nocebo phenomena.

13 Jul 2012

Disappointing result for acadesine

The adenosine-regulating agent acadesine does not reduce the occurrence of adverse outcomes in patients undergoing on-pump coronary artery bypass graft surgery, researchers say.

12 Jul 2012

Arena files lorcaserin hydrochloride MAA with Swissmedic

Arena Pharmaceuticals, Inc. announced today the filing with the Swiss health authority, Swissmedic, of a Marketing Authorization Application (MAA) for lorcaserin hydrochloride, an investigational drug candidate in Switzerland.

12 Jul 2012

Merck announces update on odanacatib Phase III trial for osteoporosis

Merck, known as MSD outside the United States and Canada, announced today an update on the Phase III trial assessing fracture risk reduction with odanacatib, Merck's investigational cathepsin K (cat-K) inhibitor.

12 Jul 2012

Enrollment complete in Phase III IND study of Spinal Restoration's Biostat System

Spinal Restoration, Inc. announced today the completion of enrollment in the Phase III Investigational New Drug (IND) study of the Biostat System. The Phase III clinical trial is a 260-subject, randomized, blinded, placebo controlled study designed to assess the ability of the Biostat System to reduce pain and improve function in patients with chronic discogenic low back pain.

12 Jul 2012

Effective therapies to reduce perioperative morbidity and mortality remain elusive

Among intermediate- to high-risk patients undergoing coronary artery bypass graft surgery, administration of the agent acadesine to regulate adenosine (a naturally occurring chemical that dilates blood flow and can improve coronary blood flow and perfusion) did not reduce all-cause death, nonfatal stroke, or need for mechanical support for ventricular dysfunction, for approximately a month after surgery, according to a study in the July 11 issue of JAMA.

12 Jul 2012

BioInvent announces data from BI-204 phase IIa study on stable atherosclerotic vascular disease

BioInvent International AB today announced data from the GLACIER phase IIa study evaluating BI-204 in patients with stable atherosclerotic vascular disease. BioInvent is developing BI-204 in collaboration with Genentech, a member of the Roche Group.

11 Jul 2012

HIV infection risk reduced by same drugs that treat HIV

People at high risk of HIV infection can reduce their risk of acquiring the disease by taking antiretroviral drugs, according to Cochrane researchers. In an update of a systematic review first published in 2009, the researchers found that uninfected people in relationships with HIV-infected partners, men who have sex with men and those in other high risk groups are at a lower risk of becoming infected with the virus if they regularly take drugs that are normally prescribed to treat people with HIV.

11 Jul 2012

Placebo News and Research

Memantine boosts memory function in people with Down syndrome

Anthera announces final set of clinical data from blisibimod Phase 2b study on SLE

Healthier levels of vitamin C can reduce inflammatory conditions

U.S. FDA approves Gilead’s Truvada to minimize risk of sexually-acquired HIV infection

AstraZeneca plans to conduct ticagrelor plus clopidogrel clinical trial for PAD

D-ribose effective in improving QOL in energy-depleted patients with FMS/CFS

Gilead receives FDA approval for Truvada to reduce risk of sexually acquired HIV-1 infection

Positive results from Alnylam’s ALN-TTR02 Phase I trial on TTR-mediated amyloidosis

Merck to present results from clinical studies on BACE inhibitors at AAIC 2012

UCB’s Neupro now available in U.S. pharmacies

Vitamin D deficiency may impair lung function in asthmatic children treated with budesonide

Viewpoints: Wis. Gov. calls Obamacare 'bad policy;' 'Do the math' before deciding on Medicaid expansion

Negative suggestion can induce symptoms of illness

Disappointing result for acadesine

Arena files lorcaserin hydrochloride MAA with Swissmedic

Merck announces update on odanacatib Phase III trial for osteoporosis

Enrollment complete in Phase III IND study of Spinal Restoration's Biostat System

Effective therapies to reduce perioperative morbidity and mortality remain elusive

BioInvent announces data from BI-204 phase IIa study on stable atherosclerotic vascular disease

HIV infection risk reduced by same drugs that treat HIV

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News